

Overall survival in patients with HR+/HER2- advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy

Hope S. Rugo<sup>1</sup>, Robert Wesolowski<sup>2</sup>, Hyo Han<sup>3</sup>, Jennifer M. Specht<sup>4</sup>, E. Claire Dees<sup>5</sup>, Erica M. Stringer-Reasor<sup>6</sup>, Peter Kabos<sup>7</sup>, Vandana Abramson<sup>8</sup>, Amy Weise<sup>9</sup>, Anne Schott<sup>10</sup>, Maysa Abu-Khalaf<sup>11</sup>, Keerthi Gogineni<sup>12</sup>, Alexander Spira<sup>13</sup>, Charlotte Moser<sup>14</sup>, Nadene Zack<sup>14</sup>, Samuel Suzuki<sup>14</sup>, Sarah Mutka<sup>14</sup>, Brian Sullivan<sup>14</sup>, Igor Gorbachevsky<sup>14</sup>, Rachel M. Layman<sup>15</sup>


<sup>1</sup>University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA; <sup>2</sup>The Ohio State University Comprehensive Cancer Center, Columbus, OH; <sup>3</sup>Moffitt Cancer Center, Tampa, FL; <sup>4</sup>Fred Hutchinson Cancer Center, University of Washington, Seattle, WA; <sup>5</sup>University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; <sup>6</sup>O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL; <sup>7</sup>University of Colorado Hospital, Aurora, CO; <sup>8</sup>Vanderbilt University Medical Center, Nashville, TN; <sup>9</sup>Henry Ford Cancer Institute, Detroit, MI; <sup>10</sup>University of Michigan, Ann Arbor, MI; <sup>11</sup>Thomas Jefferson University, Philadelphia, PA; <sup>12</sup>Emory University Hospital, Atlanta, GA; <sup>13</sup>Virginia Cancer Specialists, Fairfax, VA; <sup>14</sup>Celcuty, Minneapolis, MN; <sup>15</sup>The University of Texas MD Anderson Cancer Center, Houston, TX

BACKGROUND

- The estrogen receptor (ER), CDK4/6, and PI3K/AKT/mTOR (PAM) pathways each promote tumor cell proliferation in HR+, HER2-advanced breast cancer (ABC).
- This led to the approval of therapeutic regimens that include various combinations of endocrine therapies (ET), CDK4/6 inhibitors (CDK4/6i) and PAM inhibitors that target a single node of the PI3K/AKT/mTOR pathway for patients with HR+, HER2- ABC. [1-5]
- There is thus a strong scientific rationale to simultaneously blockade the ET, CDK4/6, and PAM pathways in both the first and second line setting to optimize anti-tumor control.
- To evaluate this hypothesis, a Phase Ib study (B2151009) of gedatolisib, a PAM (pan-PI3K and mTORC1/2) inhibitor, palbociclib, a CDK4/6 inhibitor, and ET (letrozole or fulvestrant) in women with HR+/HER2- ABC was conducted. [6]
- In this analysis, we report overall survival data for two patient subgroups evaluated in the B2151009 study:
  - Patients who had prior treatment with a CDK4/6i and fulvestrant and received gedatolisib using the intermittent schedule being studied in an ongoing Phase 3 clinical trial (VIKTORIA-1, NCT05501886).
  - Patients who were treatment naïve in the metastatic setting and were eligible for treatment with a CDK4/6i and letrozole.
- As previously reported, ORR and mPFS for both subgroups of patients compare favorably to published data for current standard of care regimens. Additionally, as previously reported, responses were observed in patients regardless of PIK3CA mutation status and few patients (<10%) discontinued treatment due to an adverse event [6,7]

Figure 1. The ER, CDK4/6, and PAM Pathways Are Interdependent Drivers of HR+/HER2- ABC

Dysregulation of these pathways promotes excessive cell proliferation and resistance to apoptosis



STUDY DESIGN



- Dosing information: Palbociclib: 125 mg/day in a 3 week on, 1 week off schedule; Letrozole: 2.5 mg/day; Fulvestrant: 500 mg intramuscular injection on cycle 1 days 1 and 15, and every 28 days ± 3 days thereafter; Gedatolisib: 180 mg IV weekly or three weeks on/one week off.
- Tumor assessment performed at baseline and every 8 weeks for at least the first 18 months of treatment until disease progression or the start of a new anti-cancer therapy.
- Endpoints: Primary – objective response per RECIST v1.1 assessed by the investigator; Secondary – safety, duration of response (DOR), and PFS.

RESULTS

Table 1: Baseline Characteristics

| Parameters                                                | 1L Line Treatment-Naïve (N=41) | 2L/3L CDK4/6i-Treated (N=27) |
|-----------------------------------------------------------|--------------------------------|------------------------------|
| Age, years                                                |                                |                              |
| Median (range)                                            | 54 (28–78)                     | 59 (34-79)                   |
| Prior Therapies – Advanced Breast Cancer, n (%)           |                                |                              |
| Prior Chemotherapy                                        | NA                             | 5 (19)                       |
| Prior SERD or SERM Therapy                                | NA                             | 10 (37)                      |
| Prior Aromatase Inhibitor Therapy                         | NA                             | 19 (70)                      |
| Prior CDK4/6 inhibitor                                    | NA                             | 26 (96)                      |
| Number of Prior Therapies – Advanced Breast Cancer, n (%) |                                |                              |
| 0                                                         | 41 (100)                       | 0                            |
| 1                                                         | 0                              | 18 (67)                      |
| 2                                                         | 0                              | 8 (30)                       |
| ≥3                                                        | 0                              | 1 (4)                        |
| Measurable Baseline Disease, n (%)                        |                                |                              |
| Yes                                                       | 38 (93)                        | 27 (100)                     |
| No                                                        | 3 (7)                          | 0                            |
| Disease Site Involved, n (%)                              |                                |                              |
| Bone Only                                                 | 1 (2)                          | 0                            |
| Bone                                                      | 26 (63)                        | 18 (67)                      |
| Brain                                                     | 0                              | 0                            |
| Liver                                                     | 15 (37)                        | 17(63)                       |
| Lung                                                      | 7 (17)                         | 6 (22)                       |
| Lymph Node                                                | 12 (29)                        | 2 (7)                        |
| Pleural Effusion                                          | 4 (10)                         | 2 (7)                        |
| Skin                                                      | 1 (2)                          | 0                            |
| Other                                                     | 35 (85)                        | 21 (78)                      |
| Number of Disease Sites Involved, n (%)                   |                                |                              |
| 1-3                                                       | 35 (85)                        | 24 (89)                      |
| ≥4                                                        | 6 (15)                         | 3 (11)                       |
| PIK3CA, n (%) <sup>a</sup>                                |                                |                              |
| Wild-type                                                 | 31 (76)                        | 15 (56)                      |
| Mutant                                                    | 9 (22)                         | 11 (41)                      |
| Unknown/Missing                                           | 1 (2)                          | 1 (4)                        |

<sup>a</sup>PIK3CA status confirmed by liquid biopsy using a central lab.  
NA, not available; SERD, selective estrogen receptor degrader; SERM, selective estrogen receptor modulator.

REFERENCES:

[1] Turner NC, et al. *N Engl J Med.* 2015;373(3):209-219.  
[2] André F, et al. *N Engl J Med.* 2019;380(20):1929-1940.  
[3] Rugo HS, et al. *J Clin Oncol.* 2020;38(suppl 15): abst 1006.  
[4] Baselga J, et al. *N Engl J Med.* 2012;366(6):520-529.  
[5] Dhakal A, et al. *Breast Cancer (Auckl).* 2020;14:1178223420944864.  
[6] Layman RM, et al. *Lancet Oncol.* 2024;25(4):474-487.  
[7] Rugo HS, et al. *ESMO Open.* 2023;8(1):101393.

ACKNOWLEDGEMENTS:

- Patients and their families/caregivers for participating in this trial
- Investigators and their support staff who participated in this work
- Celcuty Inc. for sponsoring the study

Figure 2. Overall Survival 1L Treatment-Naïve, N=41





Figure 3. Overall Survival 2L/3L CDK4/6i-Treated (N=27)



CONCLUSIONS

- Gedatolisib in combination with palbociclib and ET demonstrated encouraging preliminary efficacy in patients with HR+/HER2-ABC; mPFS was 48.4 months in the treatment-naïve subgroup and 12.9 months in the subgroup previously treated with a CDK4/6i who received gedatolisib on an intermittent schedule. [6,7]
- A subsequent analysis of these patients after additional follow-up showed encouraging OS results that compare favorably to data published for currently available standard-of-care regimens.
  - Median OS for the treatment-naïve subgroup was 77.3 months.
  - Median OS for the 2/3L CDK4/6i-treated patients who received gedatolisib on an intermittent schedule was 33.9 months.
- Combination therapy was well tolerated with few patients discontinuing treatment due to an adverse event. [6,7]
- These encouraging results support further evaluation of this combination therapy in patients with HR+/HER2- ABC.
  - VIKTORIA-1 (NCT05501886), an ongoing randomized Phase 3 study, is evaluating patients who previously received a CDK4/6i.
  - A randomized Phase 3 study evaluating treatment naïve patients (VIKTORIA-2) is planned to begin enrollment in 2025.